Despite posting record-breaking operational results and raising its annual forecast, Siemens AG is encountering a cautious response from investors. The market’s hesitation stems not from performance but from a profound strategic shift involving the planned spin-off of its medical technology unit, Siemens Healthineers.
Operational Strength and AI Ambitions
The Munich-based industrial conglomerate began its fiscal year 2026 with exceptional momentum. In the first quarter, new orders surged by 10% to reach €21.4 billion, pushing the order backlog to an unprecedented €120 billion. A primary engine of this growth is the data center business. Driven by robust U.S. demand for cloud infrastructure, this division reported a 35% increase in revenue.
In light of these results, management has upgraded its full-year outlook. The company now anticipates adjusted earnings per share in a range of €10.70 to €11.10. This operational success is complemented by a significant technological push in manufacturing. Siemens, in partnership with Nvidia, is investing approximately €200 million to transform its plant in Amberg into a fully AI-controlled factory by 2030.
Investor Uncertainty Over Healthineers Spin-off
The fundamental strength of the business, however, is being overshadowed by strategic uncertainty. The board’s proposal to spin off roughly 30% of Siemens Healthineers shares directly to existing Siemens shareholders is the central concern. This move would see Siemens relinquish its controlling majority stake, eventually holding the medical technology firm as a financial investment.
This deep corporate restructuring is generating investor unease, as specific details regarding the tax structure and precise timeline remain pending. The market’s skepticism is visibly reflected in the share price performance. After a period of sustained selling pressure in recent weeks, the stock closed at €226.80, falling below the closely watched 200-day moving average, which currently stands at €235.45.
Countermeasures and Forthcoming Catalysts
To address the technical weakness in its share price, Siemens management is deploying an accelerated share buyback program. The company plans to repurchase 18 million of its own shares by March, a move that will provide arithmetic support to earnings per share. The near-term direction for the equity is likely to be determined early in the second quarter when Siemens clarifies the exact terms of the Healthineers transaction.
The subsequent major milestone will be the quarterly report scheduled for May 13, 2026. This release will reveal whether the thriving infrastructure and data center businesses can generate sufficient momentum to outweigh the structural uncertainties introduced by the corporate overhaul.
